Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIα

Nucleic Acids Research

Volumn 31, Issue 19, 2003, Pages 5714-5722

  Vilain, Nathalie ^c   Tsai Pfugfelder, Monika ^a   Benoit, Audrey ^a,b   Gasser, Susan M ^a   Leroy, Didier ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Proteomics Platform   (Switzerland)

^c SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; HOLOENZYME; MONOMER; TENIPOSIDE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVE SITE; GENE OVEREXPRESSION; IN VITRO STUDY; MODULATION; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; YEAST CELL; CELL DIVISION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE; YEAST;

EUKARYOTA;

ADENOSINE TRIPHOSPHATE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; CELL DIVISION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE; ETOPOSIDE; HUMANS; MUTATION; PROTEIN STRUCTURE, TERTIARY; YEASTS;

EID: 0141940254     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkg737     Document Type: Article

References (38)

1. Nitiss,J.L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta, 1400, 63-81.
2. D'Arpa,P. and Liu,L.F. (1989) Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989, 163-177.
3. Corbett,A.H. and Osheroff N. (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol., 6, 585-597.
4. Pommier,Y. (1997) Cancer Therapeutics: Experimental and Clinical Agents. Humana Press, Totowa, NJ, pp. 153-173.
5. Beck,W.T., Danks,M.K., Wolverton,J.S., Kim,R. and Chen,M. (1993) Drug resistance associated with altered DNA topoisomerase II. Adv. Enzyme Regul., 33, 113-127.
6. Watt,P.M. and Hickson,I.D. (1994) Structure and function of type II DNA topoisomerases. Biochem. J., 303, 681-695.
7. Larsen,A.K. and Skladanowski,A. (1998) Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim. Biophys. Acta, 1400, 257-274.
8. Lee,M.S., Wang,J.C. and Beran,M. (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J. Mol. Biol., 223, 837-843.
9. Campain,J.A., Gottesman,M.M. and Pastan,I. (1994) A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry, 33, 11327-11332.
10. Freudenreich,C.H., Chang,C. and Kreuzer,K.N. (1998) Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4′-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone. Cancer Res., 58, 1260-1267.
11. Hinds,M., Deisseroth,K., Mayes,J., Altschuler,E., Jansen,R., Ledley,F.D. and Zwelling,L.A. (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res., 51, 4729-4731.
12. Sabourin,M., Byl,J.A., Hannah,S.E., Nitiss,J.L. and Osheroff N. (1998) A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP. J. Biol. Chem., 273, 29086-29092.
13. Sehested,M., Wessel,I., Jensen,L.H., Holm,B., Oliveri,R.S., Kenwrick,S., Creighton,A.M., Nitiss,J.L. and Jensen,P.B. (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res., 58, 1460-1468.
14. Strumberg,D., Nitiss,J.L., Rose,A., Nicklaus,M.C. and Pommier,Y. (1999) Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions. J. Biol. Chem., 274, 7292-7301.
15. Wessel,I., Jensen,L.H., Jensen,P.B., Falck,J., Rose,A., Roerth,M., Nitiss,J.L. and Sehested,M. (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res., 59, 3442-3450.
16. Dong,J., Walker,J. and Nitiss,J.L. (2000) A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J. Biol. Chem., 275, 7980-7987.
17. Hammonds,T.R., Foster,S.R. and Maxwell,A. (2000) Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis. J. Mol. Biol., 300, 481-491.
18. Patel,S., Jazrawi,E., Creighton,A.M., Austin,C.A. and Fisher,L.M. (2000) Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha. Mol. Pharmacol., 58, 560-568.
19. Vassetzky,Y.S., Alghisi,G.-C. and Gasser,S.M. (1995) DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays, 17, 767-774.
20. Nitiss,J.L. and Beck,W.T. (1996) Antitopoisomerase drug action and resistance. Eur. J. Cancer, 32A, 958-966.
21. Freudenreich,C.H. and Kreuzer,K.N. (1994) Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl Acad. Sci. USA, 91, 11007-11011.
22. Froelich-Ammon,S.J., Patchan,M.W., Osheroff,N. and Thompson,R.B. (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem., 270, 14998-15004.
23. Burden,D.A., Kingma,P.S., Froelich-Ammon,S.J., Bjornsti,M.A., Patchan,M.W., Thompson,R.B. and Osheroff,N. (1996) Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J. Biol. Chem., 271, 29238-29244.
24. Hu,T., Sage,H. and Hsieh,T.-S. (2002) ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization. J. Biol. Chem., 277, 5944-5951.
25. Leroy,D., Kajava,A.V., Frei,C. and Gasser,S.M. (2001) Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry, 40, 1624-1634.
26. Lewis,R.J., Singh,O.M., Smith,C.V., Skarzynski,T., Maxwell,A., Wonacott,A.J. and Wigley,D.B. (1996) The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J., 15, 1412-1420.
27. Chang,S., Hu,T. and Hsieh,T.-S. (1998) Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. J. Biol. Chem., 273, 19822-19828.
28. Klein,F., Laroche,T., Cardenas,M.E., Hofmann,J.F.X., Schweizer,D. and Gasser,S.M. (1992) Localization of RAP1 and topoisomerase II in nuclei and meiotic chromosomes of yeast. J. Cell Biol., 117, 935-948.
29. Gotta,M., Laroche,T. and Gasser,S.M. (1999) Analysis of nuclear organization in Saccharomyces cerevisiae. Methods Enzymol., 304, 663-672.
30. Jensen,S., Andersen,A.H., Kjeldsen,E., Biersack,H., Olsen,E.H., Andersen,T.B., Westergaard,O. and Jakobsen,B.K. (1996) Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae. Mol. Cell. Biol., 16, 3866-3877.
31. Vassetzky,Y.S., Alghisi,G.C., Roberts,E. and Gasser,S.M. (1996) Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide. Br. J. Cancer, 73, 1201-1209.
32. Lindsley,J.E. and Wang,J.C. (1993) On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J. Biol. Chem., 268, 8096-8104.
33. Lage,H., Helmbach,H., Dietel,M. and Schadendorf,D. (2000) Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br. J. Cancer, 82, 488-491.
34. Bromberg,K.D., Burgin,A.B. and Osheroff,N. (2003) A two-drug model for etoposide action against human topoisomerase IIalpha. J. Biol. Chem., 278, 7406-7412.
35. Feldhoff,P.W., Mirski,S.E., Cole,S.P. and Sullivan,D.M. (1994) Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res., 54, 756-762.
36. Wessel,I., Jensen,P.B., Falck,J., Mirski,S.E., Cole,S.P. and Sehested,M. (1997) Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res., 57, 4451-4454.
37. Mirski,S.E., Sparks,K.E., Yu,Q., Lang,A.J., Jain,N., Campling,B.G. and Cole,S.P. (2000) A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. Int. J. Cancer, 85, 534-539.
38. Wang,H., Mao,Y., Zhou,N., Hu,T., Hsieh,T.-S.D. and Liu,L.F. (2001) ATP-bound topoisomerase II as a target for antitumor drugs. J. Biol. Chem., 276, 15990-15995.